NCT00680316View on ClinicalTrials.gov

A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis

PHASE4TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Cystic Fibrosis

Interventions

DRUG

Dornase alfa

2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days

DRUG

Placebo

2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT00680316 - A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis | Biotech Hunter | Biotech Hunter